Pharmaceutical practice of acute liver injury in a patient with nintedanib-induced lung cancer complicated with interstitial pneumonia
10.12173/j.issn.1005-0698.202407015
- VernacularTitle:1例尼达尼布致肺癌合并间质性肺炎患者急性肝损伤的药学实践
- Author:
Juan ZHANG
1
;
Lihuan SHEN
;
Jiyong LIU
;
Chunmin WANG
Author Information
1. 复旦大学附属肿瘤医院药剂科(上海 200032);复旦大学上海医学院肿瘤学系(上海 200032)
- Keywords:
Nintedanib;
Lung cancer with interstitial pneumonia;
Acute liver injury;
Pharmaceutical practice
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(10):1178-1182
- CountryChina
- Language:Chinese
-
Abstract:
This article reports the pharmacotherapy process of a clinical pharmacist participating in the treatment of acute liver injury caused by nintedanib in a patient with lung cancer complicated with interstitial pneumonia.Clinical pharmacist analyzed the rapid increase of liver enzymes in patients by excluding their past drug use history,stopping suspicious drugs and searching domestic and foreign literature,and determined that the association with nidanib was very likely according to RUCAM scale.The clinical pharmacies suggesteded stopping nintedanib and taking liver protection treatment actively.The clinician adopted the suggestion,and finally the patient's liver function improved after 20 days of treatment.Clinical pharmacists demonstrate their value by analyzing the causes and characteristics of liver injury in patients,assisting physicians in the timely identification and management of adverse reactions,and participating in clinical practice.This article can provide a reference for the diagnosis and treatment of similar cases of acute liver injury.
